Johan Lundberg's research group

Molecular imaging, neuropsychopharmacology, mood and anxiety disorders

Johan Lundberg

The overriding aim of our research is to improve the treatment of major psychiatric disorders. Our main activity involves in vivo and post mortem molecular imaging to study the pathophysiology and pharmacology of mood and anxiety disorders, and to some extent autism spectrum disorders.

One vision of the group is to develop imaging markers for antidepressant treatment response. To this end, we study the molecular effect in man in vivo of different antidepressant treatments, such as Cognitive Behavioral Treatment, antidepressant drug treatment, Electro Convulsive Treatment and novel antidepressant treatments such as ketamine. We have had a focus on the serotonin system, but are performing studies also on the GABA and Glutamate systems. The development of molecular imaging analysis and statistics is an integrated part of our work.

Our work is supported by the Swedish Science Council, the Stockholm County, the Söderström-Königska foundation and from a generous private donation.

Group members

Media appearances

UR Samtiden Hjärndagen 2019 - Depression-en sjukdom och dess behandling… 

Selected publications

Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study

Lundberg J, Cars T, Lööv SÅ, Söderling J, Sundström J, Tiihonen J, Leval A, Gannedahl A, Björkholm C, Själin M, Hellner C

JAMA psychiatry 2023;80(2):167-175


International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators

Price Rb, Kissel N, Baumeister A, Rohac R, Woody Ml, Ballard Ed, Zarate Ca, Deakin W, Abdallah Cg, Feder A, Charney Ds, Grunebaum Mf, Mann Jj, Mathew Sj, Gallagher B, Mcloughlin Dm, Murrough Jw, Muthukumaraswamy S, Mcmillan R, Sumner R, Papakostas G, Fava M, Hock R, Phillips Jl, Blier P, Shiroma P, Šóš P, Su Tp, Chen Mh, Tiger M, Lundberg J, Wilkinson St, Wallace Ml

Molecular psychiatry 2022;27(12):5096-5112


Clinical and societal burden of incident major depressive disorder: A population-wide cohort study in Stockholm

Lundberg J, Cars T, Lööv SÅ, Söderling J, Tiihonen J, Leval A, Gannedahl A, Björkholm C, Själin M, Hellner C

Acta psychiatrica Scandinavica 2022;146(1):51-63


Serotonin 1B receptor density mapping of the human brainstem using positron emission tomography and autoradiography

Veldman Er, Varrone A, Varnas K, Svedberg Mm, Cselenyi Z, Tiger M, Gulyas B, Halldin C, Lundberg J



P11 (S100A10) as a potential predictor of ketamine response in patients with SSRI-resistant depression

Veldman Er, Mamula D, Jiang H, Tiger M, Ekman Cj, Lundberg J, Svenningsson P

Journal of affective disorders 2021;290():240-244


Serotonin transporter availability increases in patients recovering from a depressive episode

Svensson Je, Svanborg C, Plavén-sigray P, Kaldo V, Halldin C, Schain M, Lundberg J

Translational psychiatry 2021;11(1):264-


Serotonin transporter availability in adults with autism-a positron emission tomography study

Andersson M, Tangen Ä, Farde L, Bölte S, Halldin C, Borg J, Lundberg J

Molecular psychiatry 2021;26(5):1647-1658


A randomized placebo-controlled PET study of ketamine ' s effect on serotonin(1B) receptor binding in patients with SSRI-resistant depression

Tiger M, Veldman Er, Ekman Cj, Halldin C, Svenningsson P, Lundberg J



[11 C]raclopride positron emission tomography study of dopamine-D2/3 receptor binding in patients with severe major depressive episodes before and after electroconvulsive therapy and compared to control subjects

Tiger M, Svensson J, Liberg B, Saijo T, Schain M, Halldin C, Farde L, Lundberg J

Psychiatry and clinical neurosciences 2020;74(4):263-269


Validity and reliability of extrastriatal [11C]raclopride binding quantification in the living human brain

Svensson Je, Schain M, Plavén-sigray P, Cervenka S, Tiger M, Nord M, Halldin C, Farde L, Lundberg J

NeuroImage 2019;202():116143-


Content reviewer:
Ann Hagerborn